Is neoadjuvant therapy a pathway to improved outcomes in localized kidney cancer?January 10th 2023
At the 2023 SUO Annual Meeting, Grant Stewart, MD, PhD, discussed the potential of neoadjuvant therapy as a tool to help optimize the management of patients with localized kidney cancer.
Latest research supporting stereotactic radiotherapy for oligometastatic renal cell carcinomaDecember 5th 2022
“Stereotactic radiation can delay the initiation of systemic therapy; it can locally control oligometastatic RCC patients for as much as 2 years,” says Raquibul Hannan, MD, PhD.
Long-term follow-up supports pembrolizumab monotherapy in BCG-unresponsive NMIBCDecember 2nd 2022
Pembrolizumab monotherapy continued to demonstrate durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with BCG-unresponsive NMIBC.
Renal functional decline after radical nephrectomy strongly associated with ageDecember 2nd 2022
“We showed that in the oldest patient cohorts, age became an independent risk factor for development of de novo CKD after surgical intervention in patients who underwent radical nephrectomy," says Mimi Vu Nguyen.
Dr. Galsky explains the biomarker challenge with adjuvant immunotherapy in urothelial cancerDecember 2nd 2022
“In the adjuvant setting, we have a ‘double biomarker problem.’ Not only don’t we know which drugs work best in which patients, we actually don’t even know which patients need additional systemic treatment because many patients are already cured with surgery,” says Matthew Galsky, MD.
Neoadjuvant axitinib facilitates partial nephrectomy in ccRCC with complex renal massesDecember 2nd 2022
“Neoadjuvant axitinib seems to be successful in allowing some patients to undergo a partial nephrectomy who had previously been deemed unable to undergo this procedure," said Kevin Hakimi.
Expert discusses expanding role of SBRT in metastatic renal cell carcinomaDecember 2nd 2022
As stereotactic ablative radiation therapy enters further into the treatment space for metastatic RCC, integration of the approach is vital for physicians to focus on, according to Raquibul Hannan, MD, PhD.
Utilization of pembrolizumab in high-risk NMIBC appears similar in real-world vs clinical trial settingsDecember 1st 2022
Compared with data from the KEYNOTE-057 study, the use of pembrolizumab monotherapy in the real-world setting was similar in the treatment of patients with high-risk non-muscle invasive bladder cancer.